Information Provided By:
Fly News Breaks for August 2, 2017
AGIO
Aug 2, 2017 | 07:30 EDT
As previously reported, Leerink analyst Michael Schmidt upgraded Agios Pharmaceuticals to Outperform from Market Perform based on his higher-level conviction regarding the commercial opportunity for its IDH inhibitors Idhifa and ivosidenib in acute myeloid leukemia following Idhifa FDA-approval and his recent checks indicating a high degree of enthusiasm for these agents in the physician community pointing to potential good initial uptake. The analyst also raised his price target on the shares to $80 from $50.
News For AGIO From the Last 2 Days
There are no results for your query AGIO